No Data
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $19 to $21
Arcutis Biotherapeutics Says ZORYVE Foam 0.3% Linked To Adverse Reactions Including Headache, Nausea, And Diarrhea, With Flammability Risk And Contraindications For Liver-Impaired Patients Highlighted In Safety Profile Under FDA Review
Arcutis Biotherapeutics: Zoryve Foam Treatment Resulted in Major Improvements
Arcutis Biotherapeutics Reports Positive Phase 3 Study Results for Investigational ZORYVE Foam 0.3% in Treating Scalp and Body Psoriasis
Arcutis Announces Publication of Positive Data From ARRECTOR Trial Evaluating ZORYVE (Roflumilast) Foam 0.3% in Individuals With Psoriasis in Journal of American Medical Association Dermatology
